`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`___________
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`___________
`MYLAN PHARMACEUTICALS INC.
`Petitioner,
`v.
`BIOGEN MA INC.,
`Patent Owner.
`____________________________________________
`IPR2018-01403
`U.S. Patent No. 8,399,514
`____________________________________________
`
`PATENT OWNER’S AMENDED MANDATORY NOTICES
`
`
`
`
`
`
`Patent Owner’s Mandatory Notices
`Case No. IPR2018-01403
`
`Pursuant to 37 C.F.R. § 42.8(a)(2), Patent Owner Biogen MA Inc. provides
`
`
`
`the following updated mandatory notices.
`
`Patent Owner has updated Section II Related Matters to reflect the fact that
`
`the Federal Circuit issued its mandate in FWP IP ApS v. Biogen MA Inc., No. 2017-
`
`2109 (Fed. Cir.) on January 9, 2019, after affirming the Board and denying
`
`Appellant’s combined petition for panel rehearing and rehearing en banc on January
`
`2, 2019. In particular, Patent Owner has deleted “FWP IP ApS v. Biogen MA Inc.,
`
`No. 2017-2109 (Fed. Cir.)” from Section II.
`
`Patent Owner makes no other changes to the remaining Sections I, III, IV, and
`
`V originally provided on August 2, 2018.
`
`I.
`
`Real Party-in-Interest - 37 C.F.R. § 42.8(b)(1)
`The real party-in-interest is Biogen MA Inc., the owner of U.S. Patent No.
`
`8,399,514 (“the ’514 patent”). A corporate name change document was recorded in
`
`the U.S. Patent and Trademark Office on April 27, 2015 (reel 035507/frame 0541)
`
`and May 4, 2015 (reel 035571/frame 0926). Those documents changed the corporate
`
`name from Biogen Idec MA Inc. to Biogen MA Inc. The original assignment to
`
`Biogen Idec MA Inc. of U.S. patent application No. 13/372,426 that led to the ’514
`
`patent was recorded in the Office on May 3, 2012 (reel 028146/frame 0980).
`
`2
`
`
`
`Patent Owner’s Mandatory Notices
`Case No. IPR2018-01403
`
`
`II. Related Matters - 37 C.F.R. § 42.8(b)(2)
`The ’514 patent is currently involved in the following federal cases:
`
`Biogen International GmbH and Biogen MA Inc. v. Amneal Pharmaceuticals
`LLC et al., C.A. No. 17-823-LPS (D. Del.) (Consolidated)
`
`
`Biogen International GmbH and Biogen MA Inc. v. Mylan Pharmaceuticals
`Inc., C.A. No. 17-116-IMK (N.D. W.Va.)
`
`
`The ’514 patent has also been involved in the following proceedings before
`
`the PTAB:
`
`Coalition for Affordable Drugs V LLC v. Biogen MA Inc., IPR2015-01136 (McK)
`
`Coalition for Affordable Drugs V LLC v. Biogen MA Inc., IPR2015-01993 (RES)
`
`Biogen MA Inc. v. Forward Pharma A/S, Intf. No. 106,023 (RES), aff’d, No. 2017-
`
`2109 (Fed. Cir. Oct. 24, 2018), reh’g denied, No. 2017-2109 (January 2, 2019)
`
`The following U.S. Applications claim benefit of priority to the application
`
`that issued as the ’514 patent: 13/767,014 (abandoned), 13/804,283 (abandoned),
`
`14/718,962 (abandoned), 15/959,651 (pending), 15/983,837 (pending), and
`
`15/988,578 (pending).
`
`Patent Owner is not aware of any other related matters that would affect or be
`
`affected by this proceeding.
`
`
`
`3
`
`
`
`
`III. Lead and Back-up Counsel - 37 C.F.R. § 42.8(b)(3)
`
`Patent Owner’s Mandatory Notices
`Case No. IPR2018-01403
`
`Lead Counsel
`Barbara C. McCurdy
`Reg. No. 32,120
`Finnegan, Henderson, Farabow, Garrett
`& Dunner, LLP
`901 New York Avenue, NW
`Washington, DC 20001
`(202) 408-4047
`barbara.mccurdy@finnegan.com
`
`Back-Up Counsel
`Erin M. Sommers
`Reg. No. 60,974
`Finnegan, Henderson, Farabow, Garrett
`& Dunner, LLP
`901 New York Avenue, NW
`Washington, DC 20001
`(202) 408-4292
`erin.sommers@finnegan.com
`
`Pier D. DeRoo
`Reg. No. 69,340
`Finnegan, Henderson, Farabow, Garrett
`& Dunner, LLP
`901 New York Avenue, NW
`Washington, DC 20001
`(202) 408-4418
`pier.deroo@finnegan.com
`
`IV. Power of Attorney - 37 C.F.R. § 42.10(b)
`Pursuant to 37 C.F.R. § 42.10(b), Patent Owner confirms that a power of
`
`attorney for U.S. Application No. 13/372,426 (issued as the ’514 patent) from
`
`Biogen MA Inc. to Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
`
`(Customer Number 22,852), which includes Barbara C. McCurdy, Erin M.
`
`Sommers, and Pier D. DeRoo, was previously filed with the USPTO on April 27,
`
`2015 in Interference No. 106,023. A copy was attached as Appendix A to Patent
`
`Owner’s initial Mandatory Notices filed on August 2, 2018.
`
`4
`
`
`
`
`V.
`
`Patent Owner’s Mandatory Notices
`Case No. IPR2018-01403
`
`Service Information
`Please send all correspondence to the lead counsel at the address shown above.
`
`Under 37 C.F.R. § 42.6(e), Patent Owner consents to electronic service by e-mail to
`
`the following e-mail addresses:
`
`barbara.mccurdy@finnegan.com;
`
`erin.sommers@finnegan.com; and
`
`pier.deroo@finnegan.com.
`
`
`
`
`Dated: January 22, 2019
`
`
`
`Respectfully submitted,
`
`
`
`By: / Barbara C. McCurdy /
`Barbara C. McCurdy, Reg. No. 32,120
`Finnegan, Henderson, Farabow, Garrett
` & Dunner, LLP
`901 New York Avenue, NW
`Washington, DC 20001-4413
`(202) 408-4047
`Counsel for Patent Owner
`
`5
`
`
`
`CERTIFICATE OF SERVICE
`The undersigned hereby certifies that a copy of the foregoing Patent Owner’s
`
`Amended Mandatory Notices was served electronically via e-mail on January 22,
`
`2019, in its entirety on the following:
`
`Brandon M. White
`Perkins Coie LLP
`700 13th St., NW, Suite 600
`Washington, D.C. 20005
`Telephone: (202) 654-6206
`E-mail: bmwhite@perkinscoie.com
`
`Emily Greb
`Perkins Coie LLP
`One East Main St., Suite 201
`Madison, WI 53703
`Telephone: (608) 663-7494
`E-mail: egreb@perkinscoie.com
`
`Petitioner has agreed to electronic service.
`
`Dated: January 22, 2019
`
`By: / Catherine A. Sadler /
`Catherine A. Sadler
`Case Manager
`
`FINNEGAN, HENDERSON, FARABOW,
`GARRETT & DUNNER, LLP
`
`
`
`